Biogen | BIIB - Net Income


Biogen reported $466.5M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Gilead Sciences USD 2.18B 869M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Teva Pharmaceutical Industries USD 480M 47M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025